Abstract
Only about 20 % of brain-dead donors in Japan have been fitted in a so-called standard criteria donor for all organs including the heart, lung, liver, pancreas, and kidney. Therefore, it is very important for us to maximize the number of transplantable organs in order to resolve severe donor shortage in Japan [1]. From these aspects, the purposes of donor management are not only to stabilize donor’s hemodynamics until organ procurement surgery but also to maximize donor organ availability and to improve function of extended criteria donor organs. If organ availability is increased, more patients can be saved by organ transplantation. Maximizing donor organ availability is also the last wish of donors and donor families. However, if a transplant recipient died due to a very marginal donor organ, the donor family feels the loss of their loved one again. Therefore, the prevention of primary graft dysfunction (PGD) is essential for the donor family as well as for recipients.
Full - scale donor management begins after the patient is pronounced brain dead and his or her family agrees to donate the organ(s), especially in Japan. In general, donor management is based on the treatment of cardiac and respiratory dysfunction resulting in the improvement of hemodynamics, oxygen supply, and finally other organ function. The targets of hemodynamic parameters are systemic blood pressure >90 mmHg, central venous pressure (CVP) of 6–10 mmHg, urine output of 100 mL/h (0.5–3 mL/kg/h), and heart rate of 80–120 beats/min. As organ procurement surgery begins within 12 h after full-scale donor management is started, it is very different from the usual intensive care to stabilize hemodynamics and to maintain and improve organ function as much as possible in a short period. Moreover, it is important for the physicians who perform donor management to recognize the pathophysiology of brain death from the beginning to completion period.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Fukushima N, Ono M, Nakatani T, et al. Strategies for maximizing heart and lung transplantation opportunities in Japan. Transplant Proc. 2009;41(1):273–6.
Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation. 2006;82(11):1396–401.
Mascia L, Mastromauro I, Viverti S, et al. Management of optimize organ procurement in brain dead donors. Minerva Anestesiol. 2009;75:125–33.
Wood KE, Becker BN, McCartney JG, et al. Current concepts: care of potential organ donor. N Engl J Med. 2004;351:2730–9.
Wilhalem MJ, Pratschke J, Laskowski IA, et al. Brain death and its impact on the donor heart-lessons from animal models. J Heart Lung Transplant. 2000;19:414–8.
Audibert G, Charpentier C, Sequim-Devaux C, et al. Improvement of donor myocardial function after treatment of autonomic storm during brain death. Transplantation. 2006;82:1031–6.
Ryan JB, Hicks M, Cropper JR, et al. Functional evidence of reversible ischemic injury immediately after the sympathetic storm associated with experimental brain death. J Heart Lung Trasnplant. 2003;22:922–8.
Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;5(8):1336–41.
Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant. 1998;17:423–9.
Pennefether SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation. 1995;59:58.
Kinoshita Y, Okamoto K, Yahata K, et al. Clinical and pathological changes of the heart in brain death maintained with vasopressin and epinephrine. Pathol Res Pract. 1990;186(1):173–9.
Iwai A, Sakano T, Uenishi M, et al. Effects of vasopressin and catecholamines on the maintenance of circulatory stability in brain-dead patients. Transplantation. 1989;48(4):613–7.
Novitzky D, Wicomb WN, Cooper DKC, et al. Electrocardiographic, haemodynamic and endocrine changes occurring during experimental brain death in the chacma baboon. J Heart Transplant. 1984;4:63.
Wicomb WN, Cooper DKC, Lanza RP, et al. The effects of brain death and 24 hours storage by hypothermic perfusion on donor heart function in the pig. J Thorac Cardiovasc Surg. 1986;91:896.
Novitzky D, Wicomb WN, Cooper DKC, Tjaalgard MA. Improved cardiac function following hormonal therapy in brain dead pigs: relevance to organ donation. Cryobiology. 1987;24:1.
Kutsogiannis DJ, Pagliarello G, Doig C, Ross H, Shemie SD. Medical management to optimize donor organ potential: review of the literature. Can J Anaesth. 2006;53(8):820–30.
Powner DJ, Hendrich A, Lagler RG, et al. Hormonal changes in brain dead patients. Crit Care Med. 1990;18:785.
Gramm HJ, Meinhold H, Bickel U, et al. Acute endocrine failure after brain death? Transplantation. 1992;54:851.
Randell TT, Hockerstedt KAV. Triiodothyronine treatment in brain-dead multiorgan donors. Transplantation. 1992;54:736.
Goarin JP, Cohen S, Riou B, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg. 1996;83:41.
Wheeldon DR, Potter CDO, Oduro A, et al. Transforming the “unacceptable” donor: outcomes from adoption of a standardized donor management technique. J Heart Lung Transplant. 1995;14:734.
Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. Thyroid. 1997;7:139.
Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg. 2001;136:1377–80.
Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations. Circulation. 2002;106:836.
Zaroff JG, Rosengard BR, Armstrong WF, et al. Maximizing use of organs recovered from the cadaver donor: cardiac recommendations. J Heart Lung Transplant. 2002;21:1153.
Keller F, Hemmen T, Schoneshofer M, et al. Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. Transplantation. 1995;60:330.
Conci F, Di Rienzo M, Castiglioni P. Blood pressure and heart rate variability and baroreflex sensitivity before and after brain death. J Neurol Neurosurg Psychiatry. 2001;71:621–31.
Rapenne T, Moreau D, Lenfant F, Boggio V, Cottin Y, Freysz M, et al. Could heart rate variability analysis become an early predictor of imminent brain death? A pilot study. Anesth Analg. 2000;91:329–36.
Fukushima N, Shirakura R, Nakata S, et al. Failure of rapid autonomic augmentation of cardiac performance in transplanted hearts. Transplant Proc. 1998;30(7):3344–6. No abstract available.
D'Amico TA, Buchanan SA, Lucke JC, et al. The preservation of cardiac function after brain death: a myocardial pressure-dimension analysis. Surg Forum. 1990;41:277–9.
Sakagoshi N, Shirakura R, Nakano S, et al. Serial changes in myocardial beta-adrenergic receptor after experimental brain death in dogs. J Heart Lung Transplant. 1992;11:1054–8.
Fukushima N, Sakagoshi N, Ohtake S, et al. Effects of exogenous adrenaline on the number of the beta-adrenergic receptors after brain death in humans. Transplant Proc. 2002;34:2571–4.
Milano A, Livi U, Casula R, et al. Influence of marginal donors on early results after heart transplantation. Transplant Proc. 1993;25:3158.
Stoica SC, Satchithananda DK, Charman S, et al. Swan-Ganz catheter assessment of donor hearts: outcome of organs with borderline hemodynamics. J Heart Lung Transplant. 2002;21:615.
Ranger GS. Antidiuretic hormone replacement therapy to prevent or ameliorate vasodilatory shock. Med Hypotheses. 2002;59(3):337–40.
Guesde R, Barrou B, Leblanc I, et al. Administration of desmopressin in brain-dead donors and renal function in kidney patients. Lancet. 1998;352:1178.
Marques RG, Rogers J, Chavin KD, et al. Does treatment of cadaveric organ donors with desmopressin increase the likelihood of pancreas graft thrombosis? Results of a preliminary study. Transplant Proc. 2004;36:1048.
Hoefer D, Ruttmann-Ulmer E, Smits JM, Devries E, Antretter H, Laufer G. Donor hypo- and hypernatremia are predictors for increased 1-year mortality after cardiac transplantation. Transpl Int. 2010;23(6):589–93.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Japan
About this chapter
Cite this chapter
Fukushima, N. (2014). Management of Extended Criteria Donors. In: Asano, T., Fukushima, N., Kenmochi, T., Matsuno, N. (eds) Marginal Donors. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54484-5_2
Download citation
DOI: https://doi.org/10.1007/978-4-431-54484-5_2
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54483-8
Online ISBN: 978-4-431-54484-5
eBook Packages: MedicineMedicine (R0)